Rapid Micro Biosystems (RPID) Set to Release Earnings on Friday

Rapid Micro Biosystems (NASDAQ:RPID) is anticipated to announce its Q3 2026 results before the market opens on Friday, November 6th. Analysts expect Rapid Micro Biosystems to post earnings of ($0.2025) per share and revenue of $9.88 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, November 13, 2026 at 8:30 AM ET.

Rapid Micro Biosystems (NASDAQ:RPID) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Rapid Micro Biosystems had a negative return on equity of 177.04% and a negative net margin of 145.56%. The business had revenue of $8.05 million for the quarter, compared to analysts’ expectations of $7.88 million. On average, analysts expect Rapid Micro Biosystems to post ($0.94) EPS for the current fiscal year and ($0.72) EPS for the next fiscal year.

Rapid Micro Biosystems Trading Down 1.5%

Shares of RPID stock opened at $0.68 on Thursday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.55 and a quick ratio of 1.51. The company has a market cap of $34.18 million, a price-to-earnings ratio of -0.61 and a beta of 1.52. Rapid Micro Biosystems has a 1 year low of $0.65 and a 1 year high of $4.94. The firm has a fifty day moving average price of $1.04 and a 200-day moving average price of $2.21.

Wall Street Analyst Weigh In

RPID has been the topic of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Rapid Micro Biosystems in a research report on Thursday, October 15th. Roth Capital began coverage on Rapid Micro Biosystems in a report on Tuesday, September 29th. They set a “buy” rating and a $3.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $5.00.

About Rapid Micro Biosystems

Rapid Micro Biosystems, Inc develops automated solutions for microbial quality control in regulated manufacturing environments. Its systems are designed to detect and quantify microorganisms more efficiently than traditional manual methods, helping customers improve testing workflows, data integrity, and laboratory productivity.

The company’s primary platform, Growth Direct, supports applications including environmental monitoring and rapid microbial testing. The platform combines automated incubation, imaging, detection, and reporting with dedicated consumables, enabling pharmaceutical, biotechnology, medical device, and other manufacturers to monitor contamination risks and evaluate product sterility.

Founded in 2006 and headquartered in Lowell, Massachusetts, Rapid Micro Biosystems serves customers in the pharmaceutical and biotechnology industries, as well as other regulated markets such as medical devices and personal care.